Experts in the HIV fight say long-acting injectable PreP will go a long way in reducing HIV infections, especially among high-risk groups.

Cabotegravir is a promising HIV prevention medication that’s approved in countries like the United States. But in sub-Saharan Africa, access encounters a number of hurdles.

Prof. Philippa Musoke, the Executive Director for Makerere University - Johns Hopkins University Research Collaboration (MU-JHU), said the transmission rates among mothers getting antenatal care at Mulago and Kawempe hospitals have declined from 25 percent in 2010 to 2 percent.

Uganda will participate in a clinical trial that will evaluate the safety and efficacy of a six months long-lasting injectable, Lenacapavir (LEN), and an oral daily pill, Descovy (F/TAF) as pre-exposure prophylaxis (PrEP) products.